GCG and leukemia: Reduced intestinal GLP-2 levels were found in both mice and patients with GVHD (103), treatment with GLP-2 agonist, teduglutide, not only reduced aGVHD but also improved the outcome of SR-GVHD without compromising graft-versus-leukemia (GVL) effects in multiple mouse models (103), suggesting that GLP-2 agonist could be a novel immunosuppressive approach in SR-GVHD therapy to be tested in future clinical trials.